Could a common diabetes drug shrink prostate tumors?
NCT ID NCT04887935
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study will also look for signs that the drug may shrink tumors or cause cancer cell death. Only 24 men with intermediate- to high-risk prostate cancer will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Farxiga)
What this could lead to
If this works, it could point toward a new way to shrink prostate tumors before surgery, potentially improving outcomes.
What could go wrong
This is a very early, small pilot study with only 24 men. It primarily tests safety, not effectiveness, so the drug may not shrink tumors or cause significant benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States